US Flag logoAn official website of the United States government
BEAT AML 2.0
Vizome
Data Resource:  Vizome
Point of Contact:  
Jeffrey W. Tyner,  
Project

About This Dataset
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and clinical annotations for a large cohort of AML patients, which facilitated discovery of functional genomic correlates. Here, we present a dataset that has been harmonized with our initial report to yield a cumulative cohort of 805 patients (942 specimens). We show strong cross-cohort concordance and identify features of drug response. Further, deconvoluting transcriptomic data shows that drug sensitivity is governed broadly by AML cell differentiation state, sometimes conditionally affecting other correlates of response. Finally, modeling of clinical outcome reveals a single gene, PEAR1, to be among the strongest predictors of patient survival, especially for young patients. Collectively, this report expands a large functional genomic resource, offers avenues for mechanistic exploration and drug development, and reveals tools for predicting outcome in AML. The dataset presented in CCDC only includes pediatric and young adult cases.
Core Data Elements
Number of Cases
168
Case Sex
Female (96); Male (72)
Case Age At Diagnosis
Pediatric and Young Adult (<40 years) (168)
Case Race
Asian (6); Black or African American (7); More Than One Race (4); Native Hawaiian or Other Pacific Islander (2); White (103); Not Reported (41); Unknown (5)
Case Ethnicity
Hispanic or Latino (19); Not Hispanic or Latino (87); Not Reported (59); Unknown (3)
Case Disease Diagnosis
Acute Leukaemias of Ambiguous Lineage (4); Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms (163); Myelodysplastic Syndromes (1)
Case Tumor Site
Bone Marrow (95); Peripheral Blood (73)
Number of Samples
197
Sample Assay Method
DNA Sequencing (188); RNA Sequencing (161)
Additional Data Elements
DBGAP STUDY IDENTIFIER
DATA REPOSITORY
Grant Information
R01CA214428
An Academic-Industry Partnership to Advance Functional Genomics for Personalized Oncology
R01CA229875
Mechanisms and targeting of inflammatory cytokine-driven expansion and progression in AML
U01CA214116
Proteogenomic Translational Research Center for Clinical Proteomic
U01CA217862
Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies
U54CA224019
Architecture and Trajectory of Acquired Resistance to Therapy in AML
Published In
https://doi.org/10.1016/j.ccell.2022.07.002
Charts